Navigation Links
Ortho Evra Patch Makers Settling Cases
Date:4/21/2008

DANVILLE, Calif., April 21 /PRNewswire/ -- Ortho Evra is an adhesive, transdermal birth control patch. It is intended to release 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol into the bloodstream per 24 hours. It is replaced once a week for three weeks, and no patch is worn during the fourth week. Ortho Evra was approved by the FDA in November 2001, and over 4 million women have used Ortho Evra since its approval. Ortho Evra continues to be marketed aggressively to both consumers and physicians.

Evidence shows that Ortho Evra is dangerous and should be recalled from the market. Studies found that women using the Ortho Evra birth control patch were twice as likely to develop blood clots compared with those using oral birth control pills.

As a result of these studies, The Food and Drug Administration updated Ortho Evra's warning language to reflect that women using the patch faced twice the risk of blood clots as women on the pill.

This is not the first time there have been changes made to the warnings about Ortho Evra's risks. The first warning about the increased risks of blood clots associated with Ortho Evra was issued on November 10, 2005. In that warning, Ortho-McNeil, one of the manufacturers of Ortho Evra, admitted for the first time that women who use the patch will be exposed to up to 60% more estrogen than those taking a birth control pill with 35 micrograms of estrogen. The patch is only intended to deliver 20 micrograms of estrogen.

It is alleged that Ortho-McNeil was aware of the increased medical risks associated with Ortho Evra before the drug was approved and that, once approved, the company failed to adequately warn patients about these risks. Evidence shows that the risk of blood clots, heart attack and stroke associated with Ortho Evra is significantly higher than with oral contraceptive pills.

The contraceptive patch continues to be aggressively marketed using Olympic athletes, sexy ads and fas
'/>"/>

SOURCE Alexander Hawes, LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
2. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
3. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
4. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
5. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
7. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
8. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
9. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
10. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Charlotte, NC (PRWEB) June 03, 2015 ... announce the issuance of US Patent No. 9,044,273, ... on improving the thoraco-lumbar spinal fusion implant procedure ... replacing them with one easy-to-use disposable instrument tray. ... provide for numerous benefits over previous technology. Intelligent ...
(Date:6/2/2015)... , June 2, 2015 TapImmune, Inc. ... its institutional investors have reached an agreement whereby the ... short term warrants to provide the Company up to ... an effective S-1 registration statement. Under the restructured terms ... also call additional warrants which could result in a ...
(Date:6/2/2015)... TORONTO , June 2, 2015 /PRNewswire/ - Aptose Biosciences ... company developing new therapeutics that target the underlying mechanisms ... Drug Administration (FDA) has granted the company orphan drug ... leukemia (AML). APTO-253, a first-in-class inducer of the KLF4 ... Phase Ib clinical trial in patients with AML, high-risk ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has announced the ... , Test, Application & End User - Forecast to ... bioburden testing market is expected to reach $565.6 Million ... a CAGR of 9.8% from 2014 to 2019 ... market is segmented into consumables and instruments. The consumables ...
Breaking Biology Technology:Intelligent Implant Systems Announces US Patent Attained for Revolution™ Spinal System 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... , ROCHESTER, N.Y., Sept. 21 According to Dr. ... Utah, "for the first time we have analyzed prostate cancer and normal ... XMRV virus] ... It was also more likely to be present in ... the least aggressive tumors and over 45 percent of the most aggressive ...
... , , , SAN CARLOS, ... it will be hosting a conference call to discuss today,s announcement of a ... a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). , , ... link that is posted on the home page of Nektar,s website: ...
... ... inventory Ultra-low Freezer and Liquid Nitrogen Tank samples and efficiently manage data of any ... ... announced the release of FreezerPro 2010, Frozen sample inventory and information management system (FSIIMS). ...
Cached Biology Technology:As Predicted: Chronic Virus Found Living in Tumors of the Prostate 2Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2RURO Inc. Today Announced the Release of FreezerPro 2010, Frozen Sample Inventory and Information Management System 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... The National Human Genome Research Institute (NHGRI) of the ... three-year grant to establish a Wisconsin Center of Excellence ... effort between the University of Wisconsin in Madison, The ... be coordinated by the Medical College of Wisconsin. It ...
... rice to feed the world," says Dr. Robert Zeigler, director general ... and keep rice prices around US$300 a ton which allows ... for poor rice consumers we need to produce an additional ... for the next twenty years." Many countries do not have the ...
... CINCINNATIUsing an RNA-powered nanomotor, University of Cincinnati (UC) biomedical ... to transmit nanoscale material through a membrane. In ... Guo, PhD, members of the UC team inserted the ... into a lipid membrane. The resulting channel enabled them ...
Cached Biology News:Wisconsin Center of Excellence in Genomics Science established 2Wisconsin Center of Excellence in Genomics Science established 3'Land grabs' for rice production due to supply threats 2UC nanotech researchers develop artificial pore 2
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... Mch3 Lyophilized solid. Highly active ... kinetics, cleavage of target substrates, and inhibitor screening. ... One unit is defined as the amount of enzyme ... 235400 per hour at 37 C at saturated substrate ...
HLA-DRbeta (DA2)...
Biology Products: